Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104534 | 0.94 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104536 | 0.84 | MAPT (0.40) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104521 | 0.83 | MAPT (0.40) | ALDH1A1LMNASMN1; SMN2TSHRHPGD | |
| SCHEMBL25795122 | 0.82 | LMNA (0.63) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104368 | 0.81 | ADRB2 (0.43) | ALDH1A1KDM4ETSHRHPGDSRPK1 | |
| SCHEMBL10104444 | 0.80 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104529 | 0.78 | MAPT (0.47) | ALDH1A1LMNAMAPTGAA | |
| SCHEMBL20369638 | 0.76 | KDM4E (0.56) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104508 | 0.75 | LMNA (0.44) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL10104265 | 0.73 | LMNA (0.49) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | ALDH1A1 860/4885LMNA 180/4885KDM4E 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.